Advertisement
Advertisement

NUVL

NUVL logo

Nuvalent, Inc. Class A Common Stock

108.24
USD
Sponsored
+0.63
+0.59%
Apr 20, 16:00 UTC -4
Closed
exchange

After-Market

108.28

+0.04
+0.03%

NUVL Earnings Reports

Positive Surprise Ratio

NUVL beat 8 of 19 last estimates.

42%

Next Report

Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$1.34
Implied change from Q4 25 (Revenue/ EPS)
--
/
-15.19%
Implied change from Q1 25 (Revenue/ EPS)
--
/
+13.56%

Nuvalent, Inc. Class A Common Stock earnings per share and revenue

On Feb 26, 2026, NUVL reported earnings of -1.58 USD per share (EPS) for Q4 25, missing the estimate of -1.50 USD, resulting in a -4.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.57% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -1.34 USD, with revenue projected to reach -- USD, implying an decrease of -15.19% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
For Q4 2025, Nuvalent, Inc. Class A Common Stock reported EPS of -$1.58, missing estimates by -4.98%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.57%, changed from $104.53 before the earnings release to $103.93 the day after.
The next earning report is scheduled for May 07, 2026.
Based on 13 analysts, Nuvalent, Inc. Class A Common Stock is expected to report EPS of -$1.34 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement